KR910016719A - 벤즈옥사진 유도체, 이의 제조방법 및 질병의 치료 또는 예방을 위한 이의 용도 - Google Patents
벤즈옥사진 유도체, 이의 제조방법 및 질병의 치료 또는 예방을 위한 이의 용도 Download PDFInfo
- Publication number
- KR910016719A KR910016719A KR1019910005137A KR910005137A KR910016719A KR 910016719 A KR910016719 A KR 910016719A KR 1019910005137 A KR1019910005137 A KR 1019910005137A KR 910005137 A KR910005137 A KR 910005137A KR 910016719 A KR910016719 A KR 910016719A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- compound
- formula
- alkoxy
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 150000005130 benzoxazines Chemical class 0.000 title 1
- 230000006806 disease prevention Effects 0.000 title 1
- -1 -OOC Chemical group 0.000 claims 62
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000005441 o-toluyl group Chemical group [H]C1=C([H])C(C(*)=O)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000005554 pyridyloxy group Chemical group 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/16—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (14)
- 일반식(Ⅰ)의 화합물 및 약제학적으로 허용되는 이의 염.(Ⅰ)상기식에서, R(1) 및 R(2)는 동일하거나 상이하며 a)수소, (C1-C4)-알킬, OH, (C1-C4)-알콕시, C1또는 Br이거나 b)치환체 R(1) 및 R(2)중 하나는 a)에서 정의한 의미를 가지며, 다른하나는 CHO, (C1-C4)-알킬카보닐, (C1-C4)-알킬-CS, (C1-C4)-알킬-OOC,(C1-C4)-알콕시-CS, (C1-C4)-알킬렌-COO, (C1-C4)-알킬렌-CS-O, 하이드록시-C(C1-C4)-알킬, HS-(C1-C4)-알킬-, NO2, NH2, (C1-C4)-알킬렌-NH, 디-(C1-C4)--알킬아미노, CN, Cl,Br,I,CF3, (C1-C4)-알킬-SO, (C1-C4)-알킬-SO2, (C1-C4)-알콕시-SO,(C1-C4)-알콕시-SO2, (C1-C4)-알키노일-NH, 벤즈아미도, (C1-C4)-알콕시-CO-NH, H2NSO, (C1-C4)-알킬-NHSO, H2NSO2, (C1-C4)-알킬-NHSO2, 디-(C1-C4)-알킬-NSO2,H2NCO, (C1-C4)-알킬-NHCO, 디-(C1-C4)-알킬-NCO,H2NCS, (C1-C4)-알킬-NHCS, 디(C1-C4)-알킬-NCS, (C1-C4)-알킬-SONH, (C1-C4)-알킬-SO2NH, (C1-C4)-알콕시-SONH, (C1-C4)-알콕시-SO2NH, 니트로-(C1-C4)-알킬 또는 시아노-(C1-C4)-알킬이거나 c)R(1) 및 R(2)는 Ar-, ArO,ArCO,ArCO,ArCS,ArSO,ArSO2,ArOSO,ArOSO2,ArNHSO,ArNHSO2,ArNHCO,ArNHCS,ArSONH,ArSO2NH,ArOSONH 또는 ArSO2NH〔 여기서, Ar은 비치환되거나 1내지 3개의 동일하거나 상이한 라디칼인 (C1-C2)-알킬, (C1-C2)-알콕시, F,Cl,Br,I,CF3,CN,NO2,CO(C1-C2)-알킬 또는 SOp(C1-C2)-알킬(여기서, P는 1또는 2이다)에 의해 치환된 방향족 또는 헤테로방향족 시스템이다〕이고, R(3)는 (C1-C4)-알킬 또는 (C1-C4)-알카노일이며, R(4)는 수소, (C1-C4)-알킬 또는 (C1-C4)알카노일이고, R(3)는 및 (4)는 또한 함께 (C3-C6)-알킬렌이며, R(5)는 비치환되거나 (C1-C4)-알킬, (C1-C4)-알킬렌, (C1-C4)-알카노일, F,Cl,Br,I,OH,O(C1-C4)-알킬, ㅐ(C1-C4)-알킬렌, O(C1-C4)-알카노일, NO2,NH2, (C1-C4)-알카노일, -NH, HOOC 또는 (C1-C4)-알킬-OOC에 의해 일-또는 이치환되고, 치환된 피리딜옥시, 피리다지닐옥시, 피리미디닐옥시, 피라지닐옥시, 옥소디하이드로피라딜옥시, 옥소디하이드로피리다지닐옥시, 옥소디하이드로피리미닐옥시, 옥소디하이드로피라지닐옥시, 1H-2-피리돈-1-일, 1H-6-피리다지논-1-일, 1H-2-피리미디논-1-일, 1H-6-피리미디논-1-일, 1H-2-피리미디논-1-일, 1H-2-티오피리돈-1-일이며, 여기서, 라디칼들은 완전히 또는 부분적으로 수소화될 수 있고, R(5)는 또한 환〔여기서, X는 비치환되거나 1 내지 3개의 (C1-C2)알킬 그룹에 의해 치환된 쇄 (CH2)m로서, m은 2 내지 4이며, (CH2)m쇄는 헤테로 원자 Y (여기서, Y는 S,O 또는 NR(6)이며 R(6)는 수소 또는 (C1-C4)-알킬이다)에 의해 차단될 수 있다〕이다.
- 제1항에 있어서, R(1) 및 R(2)가 수소, 메틸, 에틸, 메톡시, 에톡시, 아세틸, 프로피오닐, 티오아세틸, 티오프로피오닐, 메톡시카보닐, 에톡시카보닐, 메톡시티오카보닐, 에톡시티오카보닐, 아세톡시, 프로피온옥시, 티오아세톡시, 티오프로피온옥시, 하이드록시메틸, 1-하이드록시에틸, 2-하이드록시에틸, 머캅토메틸, 1-머갑토에틸, 2-머캅토에틸, 메틸아미노, 에틸아미노, 디메틸아미노, 디에탈아미노, 메틸설피닐, 에틸설피닐, 메틸설포닐, 에틸설포닐, 메톡시설피닐, 에톡시설피닐, 메톡시설포닐, 에톡시설포닐, 아세트아미도, 포름아미도, 프로피온아미도, 벤즈아미도, 메톡시카보닐아미노, 에톡시카보닐아미노, 메틸아미노설피닐, 에틸아미노설피닐, 메틸아니모설포닐, 에틸아미노설포닐, N-메틸카바모일, N-에틸카바모일, N,N-디메틸카바모일, N,N-디에틸카바모일, N-메틸티오카바모일, N-에틸티오카바모일, N,N-디메틸티오카바모일, N,N-디에틸티오카바모일, 메탈설피닐아미노, 에틸설피닐아미노, 메탈설포닐아미노, 에틸설포닐아미노, 메톡시설포닐아미노, 에톡시설포닐아미노, 나트로메틸, 2-니트로에틸, 시아노메틸, 1-시아노에틸, 2-시아노에틸, 페닐, 4-또는 2-클로로페닐, o-또는 p-톨릴,페녹시, 4-또는 2-클로로페녹시, o-또는 p-톨릴옥시, 벤조일, 4-또는 2-클로로페녹시, o-또는 p-톨루오일, 벤질설피닐, 4-또는 2-클로로벤조설포닐, o-또는 p-톨릴설피닐, 벤조설포닐, 4-또는 2-클로로벤조설포닐, o-또는 p-톨릴설포닐, 벤즈옥시설피닐, 4-또는 2-클로로 벤즈옥시설피닐, o-또는 p-톨릴옥시설피닐, 벤즈아미노설피닐, 4-또는 2-클로로벤즈아미노설피닐, o-또는 p-톨릴아미노설피닐, 벤즈아미노설포닐, 4-또는 2-클로로벤즈아미노설포닐, o-또는 p-톨릴아미노설포닐, N-페닐-카바모일, N-〔4-또는 2-〕클로로페닐카바모일, o-또는 p-톨릴카바모일, N-페닐티오카바모일, N-〔4-또는 2-〕-클로로페닐티오카바모일, o-또는 P-톨릴티오카바모일, 페닐설피닐아미노, 4-또는 2-클로로페닐설피닐아미노, o-또는 p-톨릴설피닐아미노, 페닐설포닐아미노, 4-또는 2-클로로페닐설포닐아미노, o-또는 p-톨릴설포닐아미노, 페녹시설피닐아미노, 4-또는 2-클로로페녹시설피닐아미노, o-또는 p-톨릴옥시설피닐아미노, 페녹시설포닐아미노, 4-또는 2-크로로페녹시설포닐아미노, o-또는 p-톨릴옥시설포닐아미노이고, R(3)가 (C1-C4)-알킬이며, R(4)가 수소 또는 (C1-C4)-알킬이고, R(5)는 제1항에서 정의한 바와 동일한 일반식(Ⅰ)의 화합물.
- 제1항에 있어서, R(1)이 수소, Cl,Br,NO2,CN,(C1-C4)-알콕시카보닐, (C1-C4)-알킬티오 또는 페닐설포닐이고, R(2)가 수소이며, R(3)및 R(4)가 (C1-C4)-알킬이고, R(5)가 비치환되거나 (C1-C4)-알킬에 의해 치환된 1H-2-피리돈-1-일, 2-옥소피롤리딘-1-일 또는 2-옥소피레리딘-1-일인 일반식(Ⅰ)의 화합물.
- 제1항에 있어서, R(1)이 O2, CN또는 패닐설포닐이고, R(2)가 수소이며, R(3) 및 R(4)가 (C1-C4)-알킬이고, R(5)가 2-옥소피롤리디닐인 일반식(Ⅰ)의 화합물.
- 일반식(Ⅱ)의 화합물을 (a)일반식 (Ⅲ)의 화합물 또는 이의 반응성 유도체중의 하나와 반응시키거나, (b)일반식 (Ⅳ)의 화합물과 반응시켜 일반식(Ⅴ)의 화합물을 수득한 다음 폐환시켜 일반식(Ⅵ)의 화합물을 제조함을 특징으로 하여 제1항에 있어서 정의한 일반식(Ⅰ)의 화합물을 제조하는 방법.(Ⅱ)R(5) H (Ⅲ)(Ⅳ)(Ⅴ)(Ⅵ)상기식에서, R(1)내지 R(5)는 제1항에서 정의한 바와같고, L은 이탈 그룹이며, n은 1또는 2이다.
- 심장혈관계 질환을 치료 및 예방하기 위한 약제로 사용하기 위한 제1항에서 청구된 일반식(Ⅰ)의 화합물.
- 적합한 양의 제1항에서 청구한 일반식(1)의 화합물을 투여하여 심장혈관계 질환을 치료하는 방법.
- 심장/순환 계통 질병을 치료하기 위한 약제로서의 제1항에서 청구한 화합물의 용도.
- 천식에 대한 약제로서의 제1항에서 청구한 화합물의 용도.
- 평활근 질환에 대한 약제로서의 제1항에서 청구한 화합물의 용도.
- 고혈압 치료용 약제로서의 제1항에서 청구한 화합물의 용도.
- 심장보호 및 심장부정액 치료용 약제로서의 제1항에서 청구한 화합물의 용도.
- 뇌 순환 계통 질환에 대한 약제로서의 제1항에서 청구한 화합물의 용도.
- 모발 상실을 치료하기 위해 제1항에서 청구한 일반식(1)의 화합물을 국소 도포하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4010488.5 | 1990-03-31 | ||
| DE4010488A DE4010488A1 (de) | 1990-03-31 | 1990-03-31 | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR910016719A true KR910016719A (ko) | 1991-11-05 |
Family
ID=6403536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910005137A KR910016719A (ko) | 1990-03-31 | 1991-03-30 | 벤즈옥사진 유도체, 이의 제조방법 및 질병의 치료 또는 예방을 위한 이의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0450487A1 (ko) |
| JP (1) | JPH04221380A (ko) |
| KR (1) | KR910016719A (ko) |
| AU (1) | AU7387491A (ko) |
| CA (1) | CA2039319A1 (ko) |
| CS (1) | CS84891A2 (ko) |
| DE (1) | DE4010488A1 (ko) |
| FI (1) | FI911533L (ko) |
| HU (1) | HU911053D0 (ko) |
| IE (1) | IE911067A1 (ko) |
| IL (1) | IL97734A0 (ko) |
| NO (1) | NO911252L (ko) |
| PT (1) | PT97195A (ko) |
| ZA (1) | ZA912363B (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0104296D0 (sv) | 2001-12-18 | 2001-12-18 | St Jude Medical | Pacemaker |
| AU2010276537B2 (en) | 2009-07-27 | 2015-04-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| KR101911560B1 (ko) | 2010-07-02 | 2018-10-24 | 길리애드 사이언시즈, 인코포레이티드 | 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물 |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| NO3175985T3 (ko) | 2011-07-01 | 2018-04-28 | ||
| TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| WO2016074080A1 (en) | 2014-11-12 | 2016-05-19 | Emscan Corporation | Reactive near-field antenna measurement |
-
1990
- 1990-03-31 DE DE4010488A patent/DE4010488A1/de not_active Withdrawn
-
1991
- 1991-03-27 NO NO91911252A patent/NO911252L/no unknown
- 1991-03-27 EP EP91104870A patent/EP0450487A1/de not_active Withdrawn
- 1991-03-28 FI FI911533A patent/FI911533L/fi unknown
- 1991-03-28 IE IE106791A patent/IE911067A1/en unknown
- 1991-03-28 CA CA002039319A patent/CA2039319A1/en not_active Abandoned
- 1991-03-28 PT PT97195A patent/PT97195A/pt not_active Application Discontinuation
- 1991-03-28 CS CS91848A patent/CS84891A2/cs unknown
- 1991-03-28 AU AU73874/91A patent/AU7387491A/en not_active Abandoned
- 1991-03-29 JP JP3089177A patent/JPH04221380A/ja active Pending
- 1991-03-29 IL IL97734A patent/IL97734A0/xx unknown
- 1991-03-29 HU HU911053A patent/HU911053D0/hu unknown
- 1991-03-29 ZA ZA912363A patent/ZA912363B/xx unknown
- 1991-03-30 KR KR1019910005137A patent/KR910016719A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0450487A1 (de) | 1991-10-09 |
| CA2039319A1 (en) | 1991-10-01 |
| PT97195A (pt) | 1991-11-29 |
| IE911067A1 (en) | 1991-10-09 |
| DE4010488A1 (de) | 1991-10-02 |
| FI911533A0 (fi) | 1991-03-28 |
| NO911252L (no) | 1991-10-01 |
| NO911252D0 (no) | 1991-03-27 |
| IL97734A0 (en) | 1992-06-21 |
| HU911053D0 (en) | 1991-10-28 |
| ZA912363B (en) | 1991-12-24 |
| JPH04221380A (ja) | 1992-08-11 |
| FI911533L (fi) | 1991-10-01 |
| AU7387491A (en) | 1991-10-03 |
| CS84891A2 (en) | 1991-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR910016719A (ko) | 벤즈옥사진 유도체, 이의 제조방법 및 질병의 치료 또는 예방을 위한 이의 용도 | |
| FI902258A0 (fi) | Menetelmä farmakologisesti aktiivisten 13,14-dihydro-17-fenyyli-18,19,20-trinor-PGF2 -alkyyliestereiden valmistamiseksi | |
| PE20000864A1 (es) | Benzocicloheptenos, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
| MX9606176A (es) | Compuestos benzo-heterociclicos aminoalquilsustituidos. | |
| ATE111736T1 (de) | Okulare hypotensive mittel. | |
| FI943313A0 (fi) | Heterosykliset yhdisteet ja niiden valmistus ja käyttö | |
| ATE268752T1 (de) | Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung | |
| KR890000458A (ko) | 티오펜설폰아미드 녹내장 치료제 | |
| IE44105L (en) | Imidazolyl-alkyl sulphides | |
| IE42618L (en) | Piperidyl-indoles | |
| BR9509608A (pt) | Inibidores de proliferação de células de músculo liso | |
| DK685787D0 (da) | Propiophenonderivater til anvendelse ved fremstilling af et laegemiddel til behandling af pollakiuria | |
| PT89757A (pt) | Processo para a preparacao de novos derivados da xantina e de composicoes farmaceuticas que os contem, uteis no tratamento da ulcera peptica | |
| DE69518706D1 (de) | Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom | |
| DE69026016D1 (de) | Verwendung von 2-Cycloalkylamino-Oxazolinen zur Senkung oder Stabilisierung des intraokulären Druckes | |
| ATE220T1 (de) | Acylanilide mit herbicider und fungicider wirkung, verfahren zu ihrer herstellung und ihre verwendung. | |
| NO159927C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive aromatiske aminoacetylener. | |
| KR910700049A (ko) | 암치료용 조성물 및 그 치료방법 | |
| NO951060L (no) | Prostaglandin F-estere | |
| KR950008446A (ko) | 시클로헥산 유도체 | |
| ES495180A0 (es) | Procedimiento para la preparacion de n,n'-dialcohilaminoal- cohiletilendiaminas | |
| KR870002050A (ko) | 안(眼) 선택성 β-차단제 | |
| KR900014332A (ko) | 1h-이미다졸-1-아세트아미드 화합물 및 그의 제법, 및 그로 구성되는 심장 부정맥을 치료하기 위한 조성물 | |
| US6162425A (en) | Saturated, alkyl-substituted n-mercaptoacetyl heterocyclic compounds and compositions and methods for permanent shaping of hair based on same and processes for making same | |
| ATE108444T1 (de) | 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19910330 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |